# TB-500 (Thymosin Beta-4)

> TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide involved in actin regulation and cell migration. It has been studied for its apparent role in wound healing, angiogenesis, and tissue repair across cardiac and musculoskeletal systems. Preclinical research suggests the peptide may support migration of repair cells to damaged tissue and modulate inflammatory responses. Much of the supporting evidence originates from animal models, with human research remaining preliminary. It is commonly referenced in recovery-focused research contexts.

- URL: https://www.lifeconverted.com/peptides/tb-500
- Also known as: Thymosin Beta-4, TB4
- Primary category: Healing & Recovery
- Effectiveness rank: #1 in Healing & Recovery; #4 in Anti-Inflammatory; #2 in Skin & Cosmetic
- Evidence level: Moderate evidence
- Route: Subcutaneous (Typically injected systemically rather than at the injury site, since its effects are not considered strictly localized.)
- Dose range: 2-5 mg
- Dose tiers: low 2 mg; moderate 2.5 mg; high 5 mg
- Half-life: Short plasma half-life estimated in minutes to a few hours, though tissue-level effects are reported to persist longer
- Timing: Morning
- Cycle: 4-6 weeks loading, then maintenance on, 4-6 weeks off (Often cycled with an initial loading phase followed by lower-frequency maintenance dosing.)
- Storage: Store lyophilized powder frozen or refrigerated; reconstituted solution should be refrigerated and used within 2-4 weeks.

## Mechanism of action

Thymosin Beta-4 binds actin monomers, a mechanism thought to facilitate cell migration and cytoskeletal remodeling necessary for tissue repair. Animal studies suggest it may upregulate genes associated with blood vessel formation and reduce fibrosis in damaged tissue. These actions are hypothesized to underlie its studied effects on wound and cardiac tissue recovery.

## Reported benefits

- Studied for systemic wound healing support
- Investigated for angiogenesis promotion in damaged tissue
- Explored in animal models for cardiac tissue repair
- Studied for potential reduction of inflammatory scarring
- Reported anecdotally for musculoskeletal recovery

## Reported side effects

- Injection site reaction
- Headache
- Fatigue
- Lightheadedness
- Limited human safety data

## Common protocols

- 2.5 mg twice weekly subcutaneous for 4-6 weeks, then 2.5 mg weekly maintenance

## Stacking notes

Frequently discussed alongside BPC-157 in research protocols targeting combined soft-tissue repair.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer